Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin Analogues vs. Observation After PRRT in Nonfunctional Neuroendocrine Neoplasms
NCT07842172Phase 3Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Nov 2034
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Progression-Free Survival at 48 months. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN)
Beyond the preview
Go deeper on NCT07842172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842172.